RRP ISA Survey Results

    Nventa completes evaluation of second cohort in HspE7 Phase 1 cervical dysplasia trial

    by Nventa
    1/14/2008, 01/14/08

    We know that Nventa is very interested in applying HspE7 as a therapeutic vaccine to treat RRP, and this is the second itgeration of HspE7, with the new adjuvant. 

    Safety seems to have been established.

    For more, see http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=